Lupin gains 3% on launch of generic Tamiflu capsules in US market

Shares of Lupin added 3 percent intraday Monday on the back of launching of generic Tamiflu capsules in US market

The company announced the launch of its Oseltamivir Phosphate Capsules, USP having received an approval from the United States Food and Drug Administration (FDA) earlier.

Company's Oseltamivir Phosphate Capsules, USP, 30 mg (base), 45 mg (base), and 75 mg (base) are the generic equivalent of Hoffman-La Roche, Inc.'s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg.

Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older.

Oseltamivir Phosphate Capsules, USP had annual sales of approximately USD 518 million in the US (IQVIA MAT December 2017).

The company has received tentative approval for its Hydrocortisone Butyrate Lotion, 0.1% from the USFDA to market a generic version of Precision Dermatology, Inc.'s Locoid Lotion, 0.1%.

At 14:15 hrs Lupin was quoting at Rs 844, up Rs 23.10, or 2.81 percent on the BSE.

Posted by Rakesh Patil